Group 1 - The China Securities Regulatory Commission (CSRC) has requested additional information from Puyuan Precision Electronics regarding its overseas investment compliance and foreign investment restrictions [1] - Puyuan Precision Electronics has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor [1] - The CSRC's inquiries include the company's overseas subsidiary establishment procedures, compliance with foreign investment policies, and the operational status of its subsidiaries in restricted sectors [1] Group 2 - Puyuan Precision Electronics is a leading electronic measurement instrument company, recognized as the largest supplier in China and ranked eighth globally by revenue in 2024 [2] - The company designs, develops, manufactures, and delivers comprehensive electronic measurement instruments and solutions, supporting scientific exploration and industry innovation [2] - Through its "RIGOL" brand, the company serves over 100,000 end customers across more than 90 countries and regions, addressing complex testing challenges in various sectors including communications, new energy, semiconductors, and education [2]

Group 1 - The China Securities Regulatory Commission (CSRC) has requested additional information from Puyuan Precision Electronics regarding its overseas investment compliance and foreign investment restrictions [1] - Puyuan Precision Electronics has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor [1] - The CSRC's inquiries include the company's overseas subsidiary establishment procedures, compliance with foreign investment policies, and the operational status of its subsidiaries in restricted sectors [1] Group 2 - Puyuan Precision Electronics is a leading electronic measurement instrument company, recognized as the largest supplier in China and ranked eighth globally by revenue in 2024 [2] - The company designs, develops, manufactures, and delivers comprehensive electronic measurement instruments and solutions, supporting scientific exploration and industry innovation [2] - Under the "RIGOL" brand, the company serves over 100,000 end customers across more than 90 countries and regions, addressing complex testing challenges in various sectors including communications, new energy, semiconductors, and education [2]

Group 1 - The China Securities Regulatory Commission (CSRC) has requested Shengbang Co., Ltd. to provide supplementary materials regarding its overseas listing application, specifically focusing on its technology export business over the past three years and compliance issues [1] - Shengbang Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, with Huatai International and China International Capital Corporation as joint sponsors [1] - The CSRC requires that the materials submitted by Shengbang Co., Ltd. align with the contents of the prospectus, including details on the number of shares issued under different scenarios and the expected amount of funds raised [1] Group 2 - Shengbang Co., Ltd. is a comprehensive analog integrated circuit (IC) company that develops and sells high-performance analog ICs and sensors, which are fundamental components of all electronic systems [2] - As of September 21, 2025, the company has approximately 6,600 types of analog ICs and sensors across 36 product categories [2]

Group 1 - The China Securities Regulatory Commission (CSRC) has requested Shengbang Co., Ltd. to provide supplementary explanations regarding its subsidiary's "technology import and export" activities, specifically detailing the compliance and development status of its technology export business over the past three years [1] - Shengbang Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, with Huatai International and CICC serving as joint sponsors [1] - The CSRC requires that the filing materials and the prospectus regarding the issuance and listing plan must be consistent, including details on the number of shares issued under the overallotment option and the expected fundraising amount [1] Group 2 - Shengbang Co., Ltd. is a comprehensive analog integrated circuit (IC) company that develops and sells high-performance analog ICs and sensors, which are fundamental components of all electronic systems [2] - As of September 21, 2025, the company has approximately 6,600 types of analog ICs and sensor products across 36 product categories [2]

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has requested additional information from Aikobai regarding its compliance with stock incentive plans and reasons for not completing its overseas listing after previous approvals [1][2][3] Group 1: Regulatory Requirements - Aikobai is required to clarify the actual operations of its medical device production and business, including whether it has obtained the necessary qualifications and if its business scope involves areas listed in the "Negative List for Foreign Investment Access (2024 Edition)" [1] - The company must provide details on the regulatory procedures for overseas investments and foreign exchange management related to its overseas subsidiaries, along with a conclusive opinion on compliance [1] - Aikobai is also asked to explain the compliance of its implemented stock incentive plan, including the composition of participants, any relationships with other shareholders, and the legality and fairness of the plan [1] Group 2: Listing Status and Plans - The company needs to explain the reasons for not completing its overseas listing after previous approvals [3] - Aikobai is required to detail its prior A-share listing guidance and the reasons for withdrawing its application to the Shanghai Stock Exchange's Sci-Tech Innovation Board, including whether it plans to continue pursuing A-share listing and any potential impacts on the current listing [3] Group 3: Company Overview - Aikobai, established in 2013, is a biopharmaceutical company focused on discovering and developing therapies for respiratory and pediatric diseases [3] - The company has developed a pipeline of six candidate drugs, including its core product Qiruisuo Wei, which targets respiratory syncytial virus (RSV) infections, and other drugs in various clinical stages for conditions such as idiopathic pulmonary fibrosis (IPF) and attention deficit hyperactivity disorder (ADHD) [3]

Group 1 - The China Securities Regulatory Commission (CSRC) has requested Chipone Microelectronics (688630.SH) to provide additional information regarding its major shareholder, Aige Venture Capital, and the specific use of raised funds [1] - Chipone Microelectronics submitted its listing application to the Hong Kong Stock Exchange on August 31, 2025, with CICC as its sole sponsor [1] - The CSRC's inquiries include the basic situation of Aige Venture Capital, the company's business scope, and whether the raised funds will require overseas investment approvals [1] Group 2 - Chipone Microelectronics is a global leader in the direct-write lithography industry, providing core equipment for advanced information technology in the AI era [1] - The company has a complete R&D technology system that includes light sources, exposure engines, precision worktables, alignment and focusing, data links, and modular system integration design [2] - The product portfolio primarily consists of PCB direct imaging equipment and automatic line systems, as well as semiconductor direct-write lithography equipment and automatic line systems [2]

Core Viewpoint - The China Securities Regulatory Commission has issued a notice regarding Nanjing Puhui Medical Equipment Co., Ltd.'s overseas issuance and the "full circulation" of unlisted shares in the domestic market, indicating the company's plan to issue up to 34,500,000 overseas listed ordinary shares and convert 17,576,373 unlisted shares for trading on the Hong Kong Stock Exchange [1][3]. Company Overview - Puhui Medical specializes in X-ray imaging technology, expanding its product portfolio to over 100 models by April 20, 2025, supported by proprietary technologies such as X-ray tube components, high-voltage generators, and 3D imaging technology [3]. - The product range includes mobile C-arm X-ray machines, digital radiography (DR) machines, and DRF digital fluoroscopy X-ray machines, which are essential for various medical imaging applications [3]. Shareholder Information - A total of 14 shareholders are involved in the conversion of unlisted shares, with the largest shareholding being Suzhou Heji Investment Co., Ltd. holding 2,769,230 shares, followed by Zhu Lei with 2,196,000 shares [5]. - The total number of shares being converted for full circulation amounts to 17,576,373 shares [5].

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has requested additional information from Xici Technology regarding its business operations and compliance as part of its overseas listing application process [1][2]. Group 1: Regulatory Requirements - The CSRC has asked Xici Technology to provide legal opinions on the legality and compliance of its establishment and past equity changes [2]. - The company must clarify the status of its major shareholders, including any pledges or freezes on shares, and whether any prohibitive conditions apply under relevant regulations [2]. - Xici Technology is required to detail its business operations, specifically regarding its photovoltaic equipment manufacturing, and update on any ongoing litigation that may impact its overseas listing [2]. Group 2: Employee and Fund Management - The company needs to report on the progress of share transfer transactions related to its employee stock ownership plan and provide legal opinions on the fairness and compliance of the plan [2][3]. - Xici Technology must specify the intended use of funds raised from the listing, including domestic and international allocations, and confirm compliance with overseas investment regulations [3]. Group 3: Company Overview - Xici Technology is recognized as a leading IDM company in the global magnetic sensor industry, ranking sixth worldwide and first among Chinese companies based on projected 2024 revenue [3]. - The company possesses a comprehensive magnetic sensing technology portfolio and offers integrated solutions across the entire industry value chain [3].

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has requested additional information from Kefu Medical regarding its overseas listing application, focusing on compliance with regulations and operational details of its subsidiaries [1][2]. Group 1: Regulatory Compliance - CSRC requires Kefu Medical to clarify whether its domestic subsidiaries fall under the prohibitions outlined in the "Interim Measures for the Administration of Overseas Issuance and Listing of Domestic Enterprises" [1] - The company must provide details on its subsidiaries' business scope, particularly in advertising and internet information services, and confirm whether they have obtained the necessary licenses [1]. Group 2: Company Overview - Kefu Medical is one of the largest home medical device companies in China, ranking second in sales among all home medical device enterprises according to Frost & Sullivan [2]. - The company has expanded its global presence, covering over 60 countries and regions across Asia, Africa, Europe, and America, attracting a growing loyal customer base [2]. - As of June 30, 2025, Kefu Medical operates 738 self-owned stores in China, with 689 being "Jianer Hearing" service centers, providing professional hearing testing services and various quality hearing aid products [2].

Group 1 - Mindray Medical received the highest number of institutional surveys, with 184 institutions participating, including 14 fund companies, 8 securities companies, 7 private equity firms, 7 insurance companies, and 124 overseas institutions [1] - The company aims to enhance its international influence, align with its global development strategy, attract talent, and optimize shareholder structure and liquidity through its overseas listing [1] - Mindray expects a year-on-year revenue growth by Q3 2025, with a trend of quarterly improvement in revenue, particularly in international markets, which are anticipated to accelerate growth starting from Q3 [1] Group 2 - Rongbai Technology has made significant progress in developing overseas clients, including major companies like Panasonic, and has a robust overseas customer structure [2] - Dike Co. announced a cash acquisition of 62.5% of Jiangsu Jinkai Semiconductor Technology Co., which will become a subsidiary and contribute to the company's consolidated financial statements [2] - Jiangsu Jinkai focuses on storage chip packaging and testing services, with a current capacity of 3KK/month for packaging and 2.5KK/month for testing, planning to expand to 4KK/month [2] Group 3 - Huicheng Environmental has seen a dramatic increase in stock price, nearly 30 times since its low in 2022, with a recent weekly increase of over 20% [3] - The company successfully launched its 20,000 tons/year mixed waste plastic resource utilization project, with stable production following technical upgrades [3] - Jiao Cheng Ultrasonic is increasing its market share in the semiconductor packaging sector by leveraging its technology to compete against foreign equipment manufacturers [3] Group 4 - Hotgen Biotech's affiliate, ShunJing Pharmaceutical, is progressing well with its innovative drug SGC001, having completed Phase I clinical trials and preparing to initiate Phase II trials [4] - Initial results from the trials indicate that the drug's efficacy aligns with expectations, with further statistical analysis underway [4]